Dollar Amounts
USD (Millions)
Balance sheet data in USD (millions)
Doing some research...
Over 2021–2024 Humana’s balance sheet is broadly stable with modest growth in total assets from $44,358m (2021) to $46,479m (2024), a net increase of $2,121m (+4.8%). That rise is not linear: assets dipped in 2022 to $43,055m, then jumped sharply in 2023 to $47,065m before slightly retreating in 2024. Total liabilities moved from $28,255m to $30,034m over the period (+$1,779m, +6.3%), peaking in 2023 alongside assets. Stockholders’ equity was essentially flat—$16,080m in 2021 versus $16,375m in 2024 (+$295m, +1.8%)—falling in 2022 and recovering in 2023–24. The company’s leverage (liabilities/assets) edged up from ~63.7% in 2021 to ~64.7% in 2024, reflecting a slight shift toward more liabilities relative to assets while equity/shareholder cushion remained roughly constant. The 2023 inflection (large increases in both assets and liabilities) is the most noteworthy fluctuation and, for a managed-care insurer like Humana, is consistent with possible changes in insurance/reserve dynamics, higher medical cost accruals or increased premium and investment balances—any of which can swell both assets and corresponding claim or policy-related liabilities. The stable equity base suggests Humana maintained capital adequacy rather than materially deleveraging or issuing new equity, which is typical when companies prioritize dividend/share-repurchase programs or retain conservative solvency buffers. Note the 2025 row contains zeros and provides no data; to assess current capital strength or the persistence of the 2023 movements, review the company’s 2025 filings or notes on reserve development, M&A, and capital return policies.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.